Fuzionaire Diagnostics and McMaster University in Hamilton, Ontario, Canada, have signed a collaborative research agreement to develop theranostic radiopharmaceuticals.
The radiopharmaceutical will be developed using Fuzionaire Dx's HetSiFA (heteroaromatic silicon-fluoride acceptors) platform and will be evaluated at McMaster's preclinical nuclear medicine facilities, according to the firm.
Fuzionaire's HetSiFA platform is compatible with fluorine-18 (F-18), which is used for PET imaging.
